Despite Recent Declines, I’m Still Buying Royal Dutch Shell Plc And GlaxoSmithKline plc

The time to buy Royal Dutch Shell Plc (LON: RDSB) and GlaxoSmithKline plc (LON: GSK) is now, says this Fool.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

sdf

Sometimes the market presents an opportunity that’s too hard to pass up. And amidst the recent market chaos, two once-in-a-lifetime opportunities have emerged in the form of Royal Dutch Shell (LSE: RDSB) and GlaxoSmithKline (LSE: GSK).

Market sentiment couldn’t be more negative for these two companies. For example, over the past six months, Shell and Glaxo’s shares have slumped 22.3% and 13.1% respectively. Shell’s shares printed a new five-year low at the end of August. 

However, based on historic data, current trends and management predictions, these declines look to be overdone. 

Oil issues 

Shell’s shares have fallen in line with the price of oil, and many of the company’s peers have also seen their shares slump to five-year lows during the past few weeks. 

But these declines could present an opportunity for investors. Indeed, Shell is still profitable, has a rock-solid balance sheet and is slashing costs to improve margins. What’s more, Shell remains one of Europe’s largest refiners, and one of the world’s largest oil traders. First-half refining and marketing profits jumped 93% year-on-year to $5.6bn. 

Still, many investors are concerned about the state of Shell’s dividend. The company’s cash flow from operating activities slumped 42% to $13.2bn during the first half of the year, barely covering capital spending of $12.4bn. As a result, Shell’s dividend bill of $5.2bn in the first-half was paid with debt. 

Nevertheless, while the figures may suggest that Shell will have to cut its dividend payout, the company has the capacity to maintain its payout at present levels in the short term as earnings fall. Shell’s net gearing is 14.3%, and the company is selling off some assets to boost its credit profile. Also, capital spending is set to fall during the next few years as the company adjusts to the oil price environment. 

So overall, Shell’s lofty dividend yield of 7.5% looks to be safe for the time being. 

Out of favour

It seems as if Glaxo has become the FTSE 100‘s most disliked company. Since the end of April, the company’s shares have lost a fifth of their value as the City has expressed concern about the sustainability of the group’s dividend payout. 

But the City’s negative views run contrary to the projections put out by Glaxo’s own management. 

Glaxo’s management has stated that the company’s dividend payout will be maintained at 80p per share for the next few years. While I’m always sceptical about management forecasts, I’m inclined to believe that this will be the case. Glaxo’s management has a reputation to uphold, and there’s nothing more damaging to a reputation than going back on a commitment to maintaining a dividend. 

While City projections estimate that Glaxo’s dividend payout won’t be covered by earnings per share this year, figures suggest the payout will be covered by earnings next year.

Moreover, based on the number of new treatments Glaxo currently has under various stages of development, management believes that the group can steadily grow earnings by the mid-to-high single digits” from 2016 to the end of the decade, further improving dividend cover.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns shares of GlaxoSmithKline and Royal Dutch Shell B. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Close-up of a woman holding modern polymer ten, twenty and fifty pound notes.
Growth Shares

This FTSE 250 stock has beaten the index by around 10x over the last year

Jon Smith rates a FTSE 250 stock that has smashed the broader index performance and could keep going based on…

Read more »

Young woman working at modern office. Technical price graph and indicator, red and green candlestick chart and stock trading computer screen background.
Investing Articles

B&M shares are at record lows! Is now the time to consider buying?

The retailer, demoted from the FTSE 100 to the FTSE 250 last year, continues to struggle. But are B&M shares…

Read more »

Investing For Beginners

2 reasons why the stock market could hit 10,000 points by December

Jon Smith explains how the makeup of the UK stock market and the current valuation could support a move towards…

Read more »

Queen Street, one of Cardiff's main shopping streets, busy with Saturday shoppers.
Investing Articles

Why this FTSE 100 rocket is this investment trust’s number 1 holding

A UK investment trust is certainly going against the grain by having this FTSE 100 share as a high-conviction holding…

Read more »

UK financial background: share prices and stock graph overlaid on an image of the Union Jack
Investing Articles

These 2 FTSE growth stocks jumped 8% and 4.5% today!

Ben McPoland takes a closer look at a pair of FTSE stocks that are performing really well recently. Why are…

Read more »

Road 2025 to 2032 new year direction concept
Investing Articles

This under‑the‑radar FTSE 100 growth stock is also a secret dividend superstar!

Harvey Jones belatedly wakes up to a brilliant FTSE 100 growth stock that has an equally remarkable track record of…

Read more »

Business manager working at a pub doing the accountancy and some paperwork using a laptop computer
Investing Articles

Barratt Redrow share price plunges 9% on profits hit – time to consider buying?

Harvey Jones says FTSE 100 housebuilders continue to suffer with the Barratt Redrow share price slumping on a profit warning.…

Read more »

UK financial background: share prices and stock graph overlaid on an image of the Union Jack
Growth Shares

Why the next month could make or break the Lloyds share price

Jon Smith outlines two key events in coming weeks that could influence the Lloyds share price, leading him to make…

Read more »